The international Consortium for MDS @ic_MDS was launched in 2022 to foster collaborations between all #MDSsm stakeholders to promote efficient patient-centered research & faster delivery of effective therapies to patients. 1st #iwMDS in 2022 in Miami & 2nd meeting in Boston 2024

What happens in the bone marrow clonal dynamics during sepsis? We studied by looking at emergency hematopoiesis in the ICU setting 👇@ClevelandClinic @Yale #CHIP @aamdsif @MDSFoundation @olisaogbue

Officially out! Prognostic implications of #TET2 variant allele frequency in chronic myelomonocytic leukemia: a multicenter study doi.org/10.1016/j.bneo.2026.… #MDSsm #MPNsm #CMML @Bloodneoplasia @BloodPortfolio @aamdsif @MDSFoundation @ic_MDS

#Venetoclax plus #hypomethylating agent improves response rates but not survival in #TP53-mutated myelodysplastic syndromes Congratulations Somedeb @drsomedeb and team! doi.org/10.1016/j.bneo.2026.… #MDSsm @BloodPortfolio @Bloodneoplasia @aamdsif @MDSFoundation @ic_MDS

A comparison of overall survival and quality of life in patients with MDS treated with azacytidine vs decitabine doi.org/10.1016/j.bneo.2026.… #MDSsm @aamdsif @MDSFoundation @ic_MDS @BloodPortfolio @Bloodneoplasia

Many congratulations to dr Alan List for receiving the 2026 Life Achievement Award from the International Consortium for #MDSsm @ic_MDS in #iwMDSMPN2026 workshop for all the amazing contributions & his lifelong dedication to help patients with myelodysplastic syndromes @VJHemOnc

Session 11 at #iwMDSMPN26 focused on diagnosis, classification & prognostication in MDS & MDS/MPN and covered some hot topics! 📣 These included artificial intelligence, the development of the icMDS-PRO score, prognostication in TP53-mutated MDS, & incorporation of flow cytometry in diagnosis/classification. Stay tuned on VJHemOnc.com in the coming weeks to hear all the insights.🎥 ft. @Santin13Valeria, @MDella_Porta, Arjan van de Loosdrecht, @tariqkewan, & Fabio Efficace. #MDSsm #MPNsm #AIinHemOnc #HemOnc

What role does allo-SCT play in MDS? Should we transplant TP53-mutated patients? Which patients should be transplanted in the PTCy era? Does non-transplant cellular therapy have a future? Leading experts addressed these questions yesterday at #iwMDSMPN26.🩸 ft. @TalhaBadarMD, @AmyDeZern, @myeloidmalig, @dralainmina, Mohamed Kharfan-Dabaja #MDSsm #BMTsm #HemOnc

An outstanding day at the #iwMDS & #iwMPN @ic_MDS with superb faculty & talks

Characterisation of #TP53 mutational features and outcomes of acute myeloid leukaemia after allogeneic haematopoietic cell transplantation doi.org/10.1038/s41409-026-0… #LEUsm #BMTsm @BMTjournal @TheEBMT_Trainee @TheEBMT

Infection risk in myelodysplastic syndromes is dynamic and immune driven doi.org/10.1182/bloodadvance… #MDSsm @aamdsif @MDSFoundation @ic_MDS @BloodAdvances

Delighted to share our latest article in @BloodNeoplasia: Prognostic Implications of TET2 Variant Allele Frequency in Chronic Myelomonocytic Leukemia: A Multicenter Study #MDSsm #MPNsm #CMML @BloodPortfolio doi.org/10.1016/j.bneo.2026.… @aamdsif @ic_MDS @MDSFoundation @MDS_Hub

Evaluating response criteria in myelodysplastic/myeloproliferative neoplasms: a systematic review and meta-analysis doi.org/10.1016/j.bneo.2026.… @Bloodneoplasia @BloodPortfolio #MDSsm #MPNsm #CMML

Revisiting one of the most clinically useful papers on MDS. Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With #MDSsm ascopubs.org/doi/10.1200/JCO… #BMTsm @JCO_ASCO @MDella_Porta

Happy to share our newest paper on behalf of the International Consortium for Myelodysplastic Syndromes #MDSsm (@ic_MDS ) using our multi-center VALIDATE database published in @BloodCancerJnl. Recently, the randomized phase III VERONA study evaluating azacitidine plus venetoclax (VEN) versus azacitidine plus placebo in newly diagnosed higher risk (HR)-MDS showed no difference in overall survival (OS) between the two arms. However, whether the addition of VEN to HMA improves outcomes among subsets of patients with HR-MDS remains debated. We analyzed 1907 patients with HR-MDS from 31 centers in 9 countries who were treated with HMA monotherapy or HMA/VEN in the frontline setting (HMA monotherapy: n = 1773; HMA/VEN: n = 134). Responses were assessed centrally by two investigators using the IWG 2023 response criteria. Addition of VEN improved composite complete remission (cCR) rates (48.8% vs. 27.7%; p < 0.001) but not CR rates (17.1% vs. 11.7%; p = 0.16). In multivariable logistic regression analysis, cCR remained favorable for HMA/VEN vs. HMA monotherapy (Odds Ratio [OR]: 2.49; 95% CI: 1.56-3.96; p < 0.001). However, we did not observe a statistically significant difference in OS for HMA/VEN vs. HMA monotherapy (Hazard Ratio [HR]: 0.83; 95% CI: 0.64-1.07; p = 0.15). In subgroup analyses, patients with TP53 wild-type disease (HR: 0.47; 95% CI: 0.29-0.74; p = 0.002) had a significant improvement in OS and those with ≥10% bone marrow blasts (HR: 0.73; 95% CI: 0.53-1.01; p = 0.06) had a trend towards OS benefit with HMA/VEN. You can download free copy here doi.org/10.1038/s41408-026-0…

Excited to share our study on immune interactions in extramedullary (lung) acute myeloid leukemia (AML) out today at @NatImmunol !! Acute respiratory failure frequently occurs in AML due to leukemia infiltration of the lungs. The question is why and what can we do to suppress it. @VarvaraParask in the lab started this work by mapping AML:stromal and AML:immune cell interactions using scRNA-Seq and Visium/Xenium @10xGenomics spatial tools. nature.com/articles/s41590-0…

Kudos to @Dr_AmerZeidan @Ramikomrokji and @MDella_Porta’s team for leading us in this very large consortia study @ic_MDS @Hemasphere_EHA onlinelibrary.wiley.com/doi/…

Proud of our collaborative work between @ic_MDS with @HumanitasMilano which was just published in @Hemasphere_EHA. #MDSsm are biologically diverse cancers and need personalized treatment approaches. The IWG_PM introduced the MDS taxonomy, that categorizes patients into 16 genetic subgroups.

I am so thrilled to share our latest @TheEBMT guidelines on donor-derived hematological neoplasia: how to tackle these cases?? Read here👇 (link below) or listen to the @TheLancetHaem podcast! (Link below too)